Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
BackgroundBoth anlotinib and programmed death-1 (PD-1) blockade have been approved for the second-line treatment of metastatic esophageal squamous cell carcinoma (ESCC). However, the combination of these two therapies has not been evaluated. This study investigated the efficacy and safety of anlotin...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2022-08-01
|
| Sarja: | Frontiers in Oncology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fonc.2022.942678/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|